ホームページ Proteases Serine Protease inhibitor - Cysteine Protease inhibitor PMSF For research use only.

PMSF

別名：Phenylmethylsulfonyl Fluoride, Benzylsulfonyl fluoride

PMSF (Phenylmethylsulfonyl Fluoride, Benzylsulfonyl fluoride) is an irreversible serine/cysteine protease inhibitor.

PMSF 化学構造

CAS No. 329-98-6

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 29500 国内在庫あり
JPY 22000 国内在庫あり
JPY 100500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp
よく尋ねられる質問

文献中Selleckの製品使用例（25）

製品安全説明書

現在のバッチを見る： 純度： 99.91%
99.91

PMSF 関連製品

Serine Protease阻害剤の選択性比較

生物活性

製品説明 PMSF (Phenylmethylsulfonyl Fluoride, Benzylsulfonyl fluoride) is an irreversible serine/cysteine protease inhibitor.
Targets
cysteine protease [1] chymotrypsin [1]
In Vitro
In vitro Although human trypsin is less susceptible to inhibition by PMSF, this compound rapidly inactivates purified chymotrypsin from human pancreas. It also rapidly inhibits acetylcholinesterase from human red cells. [1] As an inhibitor of phosphatidylinositol-specific phospholipase C, treatment with this chemical at 2 mM almost completely inhibits carbachol-stimulated inositol incorporation into phosphatidylinositol (PI) of longitudinal smooth muscle of guinea pig ileum, while it has no effect on potassium-stimulated inositol incorporation. In contrast to its specific inhibition of carbachol-stimulated phosphoinositide turnover, this agent produces a transient inhibition of contraction by both carbachol and potassium. [3] It has been shown to inhibit the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates in Trypanosoma brucei. This inhibitor also inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei. It inhibits ethanolamine phosphate addition and inositol acylation for procyclic forms of T. brucei but not for mammalian HeLa cells. [4] This compound is the more reactive inactivator of mouse acetylcholinesterase (AChE), as the 8-fold higher BSF concentration is necessary to achieve even a 6-fold slower inactivation than that using PMSF. [7]
In Vivo
In Vivo Intraperitoneal injection of PMSF produces dose-dependent analgesia in Sprague-Dawley rats. This compound significantly enhances the analgesic effect of beta-endorphin (END) in rats. [2] Mice receiving i.p. injections of this chemical exhibit cannabinoid effects that include antinociception, hypothermia and immobility with ED50 of 86 mg/kg, 224 mg/kg and 206 mg/kg, respectively. Pretreatment with an inactive dose of this compound (30 mg/kg) enhances the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively. [5] Administration of this chemical 12 hours prior to PSP causes complete protection in organophosphorus ester-induced delayed neuropathy (OPIDN) in hens, but it administered 4 hours after PSP potentiates its neurotoxic effects. [6] Pretreatment with this compound (30 mg/kg, i.p.) prior to an injection of 1 or 10 mg/kg 3H-anandamide results 5 minutes later in enhanced brain levels of anandamide compared to those obtained with 3H-anandamide plus vehicle injection. [8] Pretreatment with it inhibits tri-ortho-cresyl phosphate (TOCP)-induced neurofilament (NF) degradation, and protects hens against the development of organophosphate-induced delayed neuropathy (OPIDN). [9] Administration of this chemical enhances the characteristic cannabimimetic effects of Δ(9)-tetrahydrocannabinol (THC) or anandamide (AEA) in ICR mice, by inhibiting the enzyme fatty acid amide hydrolase. [10]
動物実験 動物モデル Male ICR mice subjected to anandamide injection
投与量 ~1000 mg/kg
投与経路 Administered i.p. 10 minutes before i.v. anandamide injection
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04062786 Unknown status
Scheduled Heart Surgery|Valve Replacement|Coronary Artery Bypass
University Hospital Strasbourg France
 February 21 2019 --
NCT03300323 Unknown status
Peri-operative Fluid Management
St George''s Healthcare NHS Trust
 October 2017 Not Applicable
NCT02569008 Completed
Post Cardiac Surgery
St George''s University of London
 January 2014 Not Applicable
  • https://pubmed.ncbi.nlm.nih.gov/4306345/
  • https://pubmed.ncbi.nlm.nih.gov/6292607/
  • https://pubmed.ncbi.nlm.nih.gov/6090026/
  • https://pubmed.ncbi.nlm.nih.gov/7518442/
  • https://pubmed.ncbi.nlm.nih.gov/9399986/
  • https://pubmed.ncbi.nlm.nih.gov/10591511/

化学情報

分子量 174.19 化学式

C7H7FO2S
CAS No. 329-98-6 SDF Download PMSF SDFをダウンロードする
Smiles C1=CC=C(C=C1)CS(=O)(=O)F
保管

In vitro
Batch:

DMSO : 35 mg/mL ( (200.93 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 35 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
united states